A Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids in Subjects With Active Proliferative Glomerulonephritis Due to Systemic Lupus Erythematosus (SLE).

Trial Profile

A Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids in Subjects With Active Proliferative Glomerulonephritis Due to Systemic Lupus Erythematosus (SLE).

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 22 Aug 2014

At a glance

  • Drugs Abatacept (Primary) ; Mycophenolate mofetil; Prednisolone; Prednisone
  • Indications Lupus nephritis; Systemic lupus erythematosus
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Feb 2014 Results published in the Arthritis and Rheumatology.
    • 04 Jul 2012 Planned number of patients changed from 303 to 460 as reported by European Clinical Trials Database.
    • 09 Jun 2012 Results presented at the 13th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top